NEW YORK (GenomeWeb News) – Qiagen and Clovis Oncology announced after the close of the market on Monday a partnership to develop a companion diagnostic for a candidate oncology drug being developed by Clovis.

The deal covers the co-development and co-commercialization of the test to guide the use of CO-1686 being developed by Clovis to initially target an unmet clinical need in patients with epidermal growth factor receptor-driven non-small cell lung cancer who no longer respond to EGFR-inhibiting drugs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.